You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 21, 2024

RHINOCORT Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Rhinocort patents expire, and what generic alternatives are available?

Rhinocort is a drug marketed by Astrazeneca and J And J Consumer Inc and is included in two NDAs.

The generic ingredient in RHINOCORT is budesonide. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the budesonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rhinocort

A generic version of RHINOCORT was approved as budesonide by TEVA PHARMS on November 18th, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RHINOCORT?
  • What are the global sales for RHINOCORT?
  • What is Average Wholesale Price for RHINOCORT?
Drug patent expirations by year for RHINOCORT
Recent Clinical Trials for RHINOCORT

Identify potential brand extensions & 505(b)(2) entrants

University of California, Los AngelesPhase 4
Medstar Health Research InstitutePhase 4
University of Wisconsin, MadisonPhase 4

See all RHINOCORT clinical trials

US Patents and Regulatory Information for RHINOCORT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca RHINOCORT budesonide AEROSOL, METERED;NASAL 020233-001 Feb 14, 1994 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc RHINOCORT ALLERGY budesonide SPRAY, METERED;NASAL 020746-003 Mar 23, 2015 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for RHINOCORT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Dr. Falk Pharma GmbH Jorveza budesonide EMEA/H/C/004655
Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).
Authorised no no yes 2018-01-08
Stada Arzneimittel AG Kinpeygo budesonide EMEA/H/C/005653
Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.
Authorised no no yes 2022-07-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.